gMG C5 Inhibitors: Matching Therapy to Patient Needs

Novel C5 inhibitors are reshaping individualized care for generalized myasthenia gravis. Listen in to learn from Drs Muppidi, Narayanaswami, Kaminski, and Paul about persistent needs in gMG care, clinical differences among C5 inhibitors, and practical considerations for matching treatment decisions to patient goals, access, safety, and long-term adherence. Presenters: Srikanth Muppidi, MD Clinical Professor Department of Neurology and Neurological Sciences Stanford University Stanford, California Pushpa Narayanaswami, MD, FAAN Professor of Clinical Neurology Harvard Medical School Vice Chair, Clinical Operations Department of Neurology Beth Israel Deaconess Medical Center Boston, Massachusetts Henry J. Kaminski, MD Jeffrey Lieberman Professor of Neurosciences Professor of Neurology, Pharmacology & Physiology George Washington University Principal Investigator, MGNet Rare Disease Clinical Research Consortium Washington, DC Pritikanta Paul, MD Assistant Professor of Neurology University of California, San Francisco Co-Director, MG Clinic San Francisco, California Link to full program:  https://bit.ly/4aXq3Ce Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.